HK1207312A1 - Temperature stable vaccine formulations - Google Patents

Temperature stable vaccine formulations Download PDF

Info

Publication number
HK1207312A1
HK1207312A1 HK15108032.6A HK15108032A HK1207312A1 HK 1207312 A1 HK1207312 A1 HK 1207312A1 HK 15108032 A HK15108032 A HK 15108032A HK 1207312 A1 HK1207312 A1 HK 1207312A1
Authority
HK
Hong Kong
Prior art keywords
composition
vaccine
lyophilized
rpa
sugar
Prior art date
Application number
HK15108032.6A
Other languages
English (en)
Chinese (zh)
Inventor
‧盧克
J‧卢克
‧魯伊斯
C‧F‧鲁伊斯
‧麥爾斯
A‧P‧麦尔斯
‧韋爾奇
R‧W‧韦尔奇
Original Assignee
新兴产品开发盖瑟斯堡有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新兴产品开发盖瑟斯堡有限公司 filed Critical 新兴产品开发盖瑟斯堡有限公司
Publication of HK1207312A1 publication Critical patent/HK1207312A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK15108032.6A 2012-06-25 2013-06-25 Temperature stable vaccine formulations HK1207312A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664062P 2012-06-25 2012-06-25
US61/664,062 2012-06-25
US201361801385P 2013-03-15 2013-03-15
US61/801,385 2013-03-15
PCT/US2013/047712 WO2014004578A1 (en) 2012-06-25 2013-06-25 Temperature stable vaccine formulations

Publications (1)

Publication Number Publication Date
HK1207312A1 true HK1207312A1 (en) 2016-01-29

Family

ID=49783811

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108032.6A HK1207312A1 (en) 2012-06-25 2013-06-25 Temperature stable vaccine formulations

Country Status (13)

Country Link
US (1) US20150335752A1 (enExample)
EP (1) EP2863898A4 (enExample)
JP (1) JP2015525748A (enExample)
KR (1) KR20150034170A (enExample)
CN (1) CN104470506A (enExample)
AU (1) AU2013280480B2 (enExample)
CA (1) CA2877130A1 (enExample)
HK (1) HK1207312A1 (enExample)
IL (1) IL236380A0 (enExample)
IN (1) IN2015MN00038A (enExample)
RU (1) RU2014151424A (enExample)
SG (1) SG11201408262XA (enExample)
WO (1) WO2014004578A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100344A1 (en) * 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
US20170007690A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of anthrax recombinant protective antigen
WO2017007835A1 (en) 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for nanoemulsion vaccine formulations
EP3319930A4 (en) * 2015-07-07 2019-04-10 NanoBio Corporation METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
US11510871B2 (en) 2016-09-16 2022-11-29 Leukocare Ag Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US20190216925A1 (en) * 2016-09-16 2019-07-18 Leukocare Ag A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing
EP3512939A1 (en) 2016-09-16 2019-07-24 Leukocare AG A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1188171C (zh) * 1994-06-02 2005-02-09 廓德伦特控股剑桥有限公司 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CN100556400C (zh) * 2006-07-20 2009-11-04 上海交通大学 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法
WO2008079464A2 (en) * 2006-09-08 2008-07-03 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
JP2012515752A (ja) * 2009-01-22 2012-07-12 ファーマシーネ，インコーポレイテッド 安定なワクチン組成物とその使用方法

Also Published As

Publication number Publication date
EP2863898A1 (en) 2015-04-29
WO2014004578A1 (en) 2014-01-03
RU2014151424A (ru) 2016-08-20
KR20150034170A (ko) 2015-04-02
CA2877130A1 (en) 2014-01-03
CN104470506A (zh) 2015-03-25
US20150335752A1 (en) 2015-11-26
SG11201408262XA (en) 2015-01-29
IL236380A0 (en) 2015-02-26
AU2013280480B2 (en) 2018-03-15
EP2863898A4 (en) 2016-04-27
AU2013280480A1 (en) 2015-01-22
JP2015525748A (ja) 2015-09-07
IN2015MN00038A (enExample) 2015-10-16

Similar Documents

Publication Publication Date Title
HK1207312A1 (en) Temperature stable vaccine formulations
JP7109412B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓに対して免疫化するための組成物
DK2131857T3 (en) A method of producing an immunologically active adjuvansbundet dried vaccine composition
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
EP2088997B1 (en) Liquid anti-rabies antibody formulations
MX2012000158A (es) Vacunas y composiciones contra streptococcus pneumoniae.
US20230066762A1 (en) Immunogenic composition
JP2017160238A (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
US10357559B2 (en) Temperature stable vaccine formulations
US20100183675A1 (en) Stable vaccine compositions and methods of use
CA2750321A1 (en) Stable vaccine compositions and methods of use
EP1972347A1 (en) Stable vaccine powder formulations
US10293041B2 (en) Multivalent stable vaccine composition and methods of making same
US9603918B2 (en) Vaccine formulation
RU2824489C1 (ru) Фармацевтическая композиция, содержащая полинуклеотиды, и её применение для предотвращения или лечения covid-19
WO2025149609A1 (en) Formulations for staphylococcus aureus vaccine
Palmer et al. Recombinant Protein D from Haemophilus influenzae Induces Mouse Bactericidal Antibodies Against Typeable and Non-Typeable Haemophilus influenzae, which Partially Protect Infant Rats Against Serotype b Bacteraemia
WO2022074061A1 (en) Cholera vaccine formulation
NZ614460B2 (en) Vaccines and compositions against streptococcus pneumoniae